Ibrutinib now cheaper for patients
Monday, 09 October 2017
The Leukaemia Foundation welcomes the Federal Government’s announcement that the cancer medicine, IMBRUVICA® (ibrutinib) will be added to Pharmaceutical Benefits Scheme (PBS) from 1 December 2017.
Bill Petch, CEO at the Leukaemia Foundation said this announcement is an important step forward for people living with Read More
The latest on CAR T-cell therapy research
Wednesday, 28 June 2017
A clinical trial will test advancements in chimeric antigen receptor (CAR) T-cell therapy developed in Australia and funded by the Leukaemia Foundation*.
The clinical trial opened in Sydney in August 2017 for people with relapsed B-cell leukaemias and lymphomas, following TGA and ethics approvals.
World-first blood test could provide more effective, less invasive blood cancer treatments
Tuesday, 20 June 2017
A world-first “liquid biopsy” could soon offer you direct access to a simple blood test to help in the monitoring and management of your blood cancer treatment.
The blood test promises a new era of less invasive, more precise and effective management of your blood cancer, in
15-year Holden partnership celebrated
Thursday, 15 June 2017
A brand new Astra, Trailblazer and Trax were unveiled at the recent joint celebration acknowledging Holden’s 15 years of support for the Leukaemia Foundation’s Patient Transport Program in Victoria, bringing their fleet support from 17 vehicles to 20.
Many of our amazing volunteer drivers, supporters of the
Australians living with MPN step closer to accessing Pegasys treatment
Thursday, 08 June 2017
The drug interferon alfa-2a (Pegasys®) was finally listed on the agenda of the Pharmaceutical Benefits Advisory Committee (PBAC) meeting on March 8 and many Australians are awaiting the results of the discussion.
For Nathalie Cook, who was diagnosed with MPN in 2008, this achievement was especially exciting
Life-saving Hodgkin lymphoma treatment now available on PBS
Sunday, 02 April 2017
Participants of two Leukaemia Foundation surveys have helped inform the Pharmaceutical Benefits Advisory Committee of the benefits of brentuximab vedotin, a potentially life-saving treatment for Australians diagnosed with a form of Hodgkin lymphoma*, supporting its listing on the PBS from April 1.
The PBS listing of brentuximab
Getting patients faster access to clinical trials and effective treatments
Sunday, 29 January 2018
We are pleased to announce the recent appointment of Caroline Turnour as the Leukaemia Foundation’s General Manager of Research, Advocacy and Services.
A member of our national management team, Caroline will be a strong and influential advocate for the rights of all people and families affected by
Ageing population increasing Queensland’s blood cancer burden
Tuesday , 17 January 2017
Blood cancer death rates in Queensland have soared by a third in just 10 years, a further symptom of the country’s ageing population, according to a new analysis.
The Leukaemia Foundation’s investigation shows the number of Australians dying from blood cancer is now DOUBLE those losing
Breakthrough cancer drug venetoclax approved for use in Australia
Tuesday, 10 January 2017
New anti-cancer drug, venetoclax which has the power to ‘melt away’ advanced forms of chronic lymphocytic leukaemia (CLL) was recently granted approval by the Australian Therapeutic Goods Administration (TGA).
The drug will be marketed as VenclextaTM and is approved for Australians with relapsed or refractory CLL with 17p
Holden donates 17 Commodores to help Australians get to life-saving treatment
Sunday, 29 October 2016
Finding a way to attend vital appointments can be an added burden to someone already facing a life-threatening blood cancer diagnosis.
Holden are helping to alleviate this stress and provide better journeys to treatment by supplying the Leukaemia Foundation’s nationwide Patient Transport Program with 17 new Commodores.